|
受注:045-509-1970 |
技術サポート:tech@selleck.co.jp 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
|
Synonyms | N/A | Storage (From the date of receipt) |
3 years -20°C powder 1 years -80°C in solvent |
| 化学式 | C13H20N2O4 |
|||
| 分子量 | 268.31 | CAS No. | 1632032-53-1 | |
| Solubility (25°C)* | 体外 | Water | 53 mg/mL (197.53 mM) | |
| DMSO | Insoluble | |||
| Ethanol | Insoluble | |||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
||||
| 製品説明 | LB-100は、BxPc-3細胞で0.85 μM、Panc-1細胞で3.87 μMのIC50を示す水溶性のプロテインホスファターゼ2A(PP2A)阻害剤です。 |
|---|---|
| in vitro | LB-100 inhibits the cell growth with IC50 of 2.3 μM (in BxPc-3) or 1.7 μM (in Panc-1 cell). In BxPc-3, Panc-1, and SW1990 cells, this compound reduces the PP2A activity by 30-50%. It increases concentration of doxorubicin within cells (2.5 fold to control) and sensitizes tumor cells to the cytotoxicity of doxorubicin. This chemical increaseds VEGF secretion, and thus enhances HIF-1α-VEGF mediated angiogenesis. |
| in vivo | In a mouse pancreatic cancer xenograft model, LB-100 (2 mg/kg, i.p.) enhances chemotherapy of doxorubicin. This compound causes higher density of microvessel in tumors and rapid blood flow at the surface of tumors. |
| キナーゼアッセイ | PP2A activity assays | |
|---|---|---|
| Cultured pancreatic cancer cells are treated with IC50 of LB-100 for each cell line or equal volume of vehicle for 2 hours, and PP2A activity assays are then performed using Ser/Thr phosphatase assay kit. Cells are lysed with an ultrasonic cell disruptor, and the PP2A concentration is measured using a Ser/Thr phosphatase assay kit according to the instructions. Assays for each cell line are performed in triplicate. | ||
| 細胞アッセイ | 細胞株 | BxPc-3, and Panc-1 cell lines |
| 濃度 | ~ 10 μM | |
| 反応時間 | 48 h | |
| 実験の流れ | Cytotoxicity is conducted by using a Cell Counting Kit-8. Cells are seeded in 96-well plates with a density of 3000 cells per well and are assessed after treatments following the CCK-8 protocol. Relative cytotoxicity is expressed as a percentage of specific controls. |
|
| 動物実験 | 動物モデル | BALB/c nude mice bearing Panc-1 xenograft |
| 投薬量 | 2 mg/kg | |
| 投与方法 | i.p. | |
|

Data from [Data independently produced by , , Exp Mol Med, 2018, 50(7):83]

Data from [Data independently produced by , , Am J Pathol, 2017, 187(8):1736-1749]
| PPP2R1A mutations portend improved survival after cancer immunotherapy [ Nature, 2025, 10.1038/s41586-025-09203-8] | PubMed: 40604275 |
| Inter-platelet communication driving thrombus formation is regulated by extracellular calpain-1 cleavage of connexin 62 [ Haematologica, 2025, 110(8):1822-1833] | PubMed: 40045892 |
| RNA polymerase II subunit 5-mediating protein limits TLR4-induced innate immune activation in macrophages by inhibiting IKKβ/NF-κB signaling during sepsis [ Cell Commun Signal, 2025, 23(1):274] | PubMed: 40495190 |
| LB-100 Enhances Drugs Efficacy Through Inhibition of P-Glycoprotein Expression in Multidrug-Resistant Glioblastoma and Non-Small Cell Lung Carcinoma Cellular Models [ Pharmaceutics, 2025, 17(2)189] | PubMed: 40006556 |
| PP2A attenuates α-amanitin-induced liver injury by promoting autophagy and inhibiting apoptosis in mouse models [ Chem Biol Interact, 2025, 417:111558] | PubMed: 40379039 |
| Oncogene Silencing via ecDNA Micronucleation [ bioRxiv, 2025, 2025.04.15.648906] | PubMed: 40321211 |
| CUL4B mutations impair human cortical neurogenesis through PP2A-dependent inhibition of AKT and ERK [ Cell Death Dis, 2024, 15(2):121] | PubMed: 38331954 |
| PTGER4 signaling regulates class IIa HDAC function and SPINK4 mRNA levels in rectal epithelial cells [ Cell Commun Signal, 2024, 22(1):493] | PubMed: 39396982 |
| The immunosuppressive drug cyclosporin A has an immunostimulatory function in CD8+ T cells [ Eur J Immunol, 2024, e2350825.] | PubMed: 38650034 |
| An AMBRA1, ULK1 and PP2A regulatory network regulates cytotoxic T cell differentiation via TFEB activation [ Sci Rep, 2024, 14(1):31838] | PubMed: 39738384 |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。